Showing posts with label pharmacogenetics. Show all posts
Showing posts with label pharmacogenetics. Show all posts

Saturday, January 9, 2010

How will medical education change in the future?

Medical school has evolved dramatically over the past few decades. Think about how many drugs medical students had to learn 50 years ago. Compare that to today, where new classes of pharmacological agents are being developed practically every year. On top of those changes, we're seeing so much happening in the world of molecular medicine, genomics, pharmacogenetics, personalized medicine, and medical devices. Plus, we're inventing new treatments and applying new strategies to treat certain diseases and conditions. The study of medicine has become much more complex over the years.

The traditional medical school in the United States if 4 years long and it's a graduate program for students who have completed a 4-year college degree. There are a handful of medical schools that combine undergrad with medical school so that you can complete your education in a shorter period of time.

Given all the recent advances in medical technology, disease management, and pharmacology, is 4 years of medical school enough? In the future, will medical school be longer than 4 years? Maybe residency will get longer. There are some people out there who are actively advocating that certain residencies should be longer because physicians who complete those residency training programs are not feeling properly equipped to practice medicine.

Friday, May 22, 2009

Coumadin and Pharmacogenetics


I know many people who have to take warfarin (Coumadin) because they have a history of venous thromboembolism or VTE. Blood clots can be deadly. Coumadin isn't an easy drug to take. The effects of the drug can really vary based on what you eat, especially if you eat anything that is high in vitamin K like green leafy vegetables. Coumadin acts by blocking the actions of vitamin K (it's often called a vitamin K antagonist).

The The International Warfarin Pharmacogenetics Consortium researchers have found that "the use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach." Sounds pretty interesting, doesn't it? Take a look at the New England Journal of Medicine (NEJM) article here if you'd like to read more about this interesting pharmacogenetic algorithm.